XXXX in @entity1252 : a cohort review.

@entity1 @entity1667 @entity66 @entity548 @entity1333 @entity1252 @entity786
UNASSIGNED: @entity548 ( @entity548 ) is a rare but potentially catastrophic manifestation with a high mortality. Among @entity66 , it occurs most frequently in @entity1 with @entity1252 ( @entity1252 ) and systemic @entity1333 . Despite new diagnostic tools and therapies, it remains a diagnostic and therapeutic challenge. The aim of this work was to characterize the @entity1252 @entity1 with an episode of @entity548 followed in our Clinical Immunology Unit (CIU). A retrospective chart review was carried out for all @entity1 with @entity1252 followed in CIU between 1984 and the end of 2013. We reviewed the following data: demographic characteristics, clinical and laboratory data, radiologic investigations, histologic studies, treatment, and outcome. We identified 10 episodes of @entity548 , corresponding to seven @entity1 , all female. These represent 1.6% of @entity1252 @entity1 followed in our Unit. The age at @entity548 attack was 42.75        18.9 years. The average time between diagnosis of @entity1252 and the onset of @entity548 was 7.1 years. Three @entity1 had the diagnosis of @entity1252 and the @entity548 attack at the same time. Disease activity according to SLEDAI was high, ranging from 15 to 41. All @entity1 were treated with @entity1667 , 37.5% @entity786 and 28.6% plasmapheresis. The overall mortality rate was 28.6%.
